Welcome to our dedicated page for ASP Isotopes SEC filings (Ticker: ASPI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ASP Isotopes Inc. discloses material events, capital structure, governance matters, operating results and project risks through its SEC filings. The company’s 8-K reports document business updates tied to isotope enrichment, PET Labs radiopharmaceutical operations, Quantum Leap Energy, research collaborations, advisory-board matters, and Renergen-related helium and LNG project disclosures.
Its filings also include Regulation FD exhibits, amended 8-K risk-factor disclosures, and a Form 12b-25 notice for annual-report timing. Recurring disclosure subjects include ASP and Quantum Enrichment technologies, Pretoria enrichment facilities, nuclear medicine and semiconductor isotope applications, nuclear fuel-cycle initiatives, financial position, forward-looking statements, permitting, development costs, and operational risks at the Virginia Gas Project.
ASP Isotopes Inc. reported operational progress at its Silicon-28 enrichment facility in Pretoria, South Africa. The company has successfully restarted the first 18 stages of the plant after nine months of engineering enhancements to non-core components such as valves, compressors, and piping, and these stages have operated for over three weeks at target enrichment levels.
The company has signed three commercial contracts to supply enriched Silicon-28 to U.S.-based customers and expects initial commercial shipments to begin in Q3 2026. Earlier, it shipped first samples in August 2025, with independent analysis confirming enrichment performance. The release highlights Silicon-28’s potential importance for quantum computing and next-generation semiconductors.
ASP Isotopes Inc. furnished an update under Regulation FD by releasing its latest investor presentation on May 20, 2026. The presentation is available on the company’s website home page.
The company states the presentation is not deemed “filed” under the Exchange Act or Securities Act and will not be incorporated by reference into other SEC filings. It includes safe harbor language indicating that some content consists of forward-looking statements subject to risks described in ASP Isotopes’ most recent Form 10-K and other SEC reports.
ASP Isotopes Inc. (ASPI) reported sharp growth in early-stage revenue but remains deeply loss-making as it scales new businesses. For the quarter ended March 31, 2026, revenue rose to $4.2 million from $1.1 million a year earlier, driven by nuclear medicine doses and initial LNG and helium sales.
The company posted a $26.7 million net loss from continuing operations, widening from $8.5 million, reflecting higher R&D and selling, general and administrative expenses as it builds enrichment and gas projects. After income from discontinued operations, overall net loss was $7.1 million, or $0.06 per share.
ASPI ended the quarter with $207.3 million in cash and cash equivalents and $83.2 million in short‑term investments, and management believes this will fund operations for more than 12 months. The acquisition of Renergen added natural gas properties and created a new helium and LNG segment, while Skyline’s deconsolidation is now reported as discontinued operations.
ASP Isotopes Inc. notified the SEC it cannot timely file its Form 10-Q for the period ended March 31, 2026. The company states the delay stems from obtaining and compiling required information and says it will file the Form 10-Q no later than the fifth calendar day following the prescribed due date.
The notification was signed by Heather Kiessling, Chief Financial Officer, on May 15, 2026.
ASP Isotopes Inc., through its wholly owned subsidiary Quantum Leap Energy, announced a non-binding Memorandum of Understanding with a European nuclear technology company to explore a long-term collaboration for advanced nuclear fuel supply.
The MOU covers potential supply of high assay low enriched uranium (HALEU) with uranium-235 content greater than 10%. The parties plan technical and economic assessments, with a framework where the partner could provide uranium feedstock to Quantum Leap Energy’s planned conversion and enrichment facilities, and Quantum Leap Energy could enrich and potentially deconvert it for delivery.
The MOU runs through December 31, 2030, and contemplates non-binding estimates of HALEU quantities, with potential deliveries beginning in 2028 and volumes scaling up through 2036, aligned with the partner’s reactor development timeline and fuel needs.
ASP Isotopes Inc. reported that its wholly owned subsidiary, Quantum Leap Energy LLC (QLE), has appointed Dr. Peter S. Fiske to QLE’s Strategic Advisory Board. QLE focuses on innovative technologies across the nuclear fuel cycle, including uranium enrichment and lithium isotope separation, using proprietary Aerodynamic Separation Process and Quantum Enrichment technologies.
Dr. Fiske previously led the U.S. Department of Energy’s five-year, $110 million National Alliance for Water Innovation hub and has extensive experience in technology commercialization, government partnerships, and advanced materials. The press release also reiterates QLE and ASP Isotopes’ use of forward-looking statements subject to significant technical, regulatory, and funding risks.
ASP Isotopes Inc. filed Amendment No. 1 to its annual report for the year ended December 31, 2025 to add Part III information on directors, executive officers, compensation, ownership and auditor fees. The amendment does not update financial statements and should be read together with the original filing.
For 2025, CEO Paul Mann received total compensation of about $16.8 million, including salary, cash bonus and significant equity awards. The filing also discloses that non‑affiliate market value was approximately $399.8 million and that 125,903,447 common shares were outstanding as of April 29, 2026.
BlackRock, Inc. files an amended Schedule 13G reporting beneficial ownership of 8,274,763 shares of ASP Isotopes Inc. The amendment (Amendment No. 1) lists 8,274,763 shares beneficially owned, representing 6.6% of the class, with 8,117,277 shares of sole voting power and 8,274,763 shares of sole dispositive power. The cover shows a 03/31/2026 reference and the filing is signed on 04/27/2026. The filing states the holdings reflect aggregated positions of Reporting Business Units of BlackRock and notes various persons may have rights to dividends or proceeds but no other single person holds more than 5%.
ASP Isotopes Inc. COO Robert Ainscow reported an open-market sale of 22,500 shares of Common Stock at a weighted average price of $5.205 per share. According to the disclosure, this was a "sell to cover" transaction under a Rule 10b5-1 trading plan adopted on June 9, 2025 to cover tax withholding obligations tied to vesting restricted stock awards. After the sale, he directly held 1,490,317 shares, so the transaction represents a small portion of his overall position.
ASP Isotopes Inc. Chief Financial Officer Heather Kiessling reported an open-market sale of 23,124 shares of common stock on April 15, 2026 at a weighted average price of $5.478 per share. The footnotes state this was a "sell to cover" under a Rule 10b5-1 trading plan adopted on December 19, 2025 to cover tax withholding obligations tied to vesting restricted stock awards. After the sale, she directly holds 709,376 shares of ASP Isotopes common stock.